Literature DB >> 27864740

Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia.

Zsuzsanna Gaál1, Éva Oláh2, László Rejtő3, Bálint László Bálint4, László Csernoch5.   

Abstract

Disruption of epigenetic regulation and characteristic metabolic alterations (known as the Warburg-effect) are well-known hallmarks of cancer. In our study we investigated the expression levels of microRNAs and histone deacetylase enzymes via RT-qPCR in bone marrow specimens of adult patients suffering from hematological malignancies (total cohort n = 40), especially acute myeloid leukemia (n = 27). The levels of the three examined Warburg-effect related microRNAs (miR-378*, miR-23b, miR-26a) positively correlated with each other and the oncogenic miR-155 and miR-125b, while negatively with the level of the tumorsuppressor miR-124. Significant relationships have been confirmed between the levels of SIRT6, HDAC4 and the microRNAs listed above. In NPM1-mutated AML (n = 6), the level of miR-125b was significantly lower than in the group of AML patients not carrying this mutation (n = 13) (p < 0.05). In M5 FAB type of AML (n = 5), the level of miR-124 was significantly higher compared to the M2 group (n = 7) (p < 0.05). In two cases of FAB M5 AML, the levels of SIRT6 and miR-26a increased during the first 4 weeks of treatment. In the total cohort, white blood cell count at the time of the diagnosis significantly correlated with the levels of HDAC4, SIRT6, miR-124 and miR-26a. Our results suggest that Warburg-effect related microRNAs may have important role in the pathogenesis of leukemia, and the potential oncogenic property of HDAC4 and SIRT6 cannot be excluded in hematological malignancies. Elevated level of miR-125b can contribute to adverse prognosis of AML without NPM1 mutation. The prevailment of the tumorsuppressor property of miR-124 may depend on the accompanying genetic alterations.

Entities:  

Keywords:  Acute myeloid leukemia; Anti-oncomiR; Histone deacetylase; Warburg-effect; microRNA; oncomiR

Mesh:

Substances:

Year:  2016        PMID: 27864740     DOI: 10.1007/s12253-016-0151-9

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  31 in total

Review 1.  Cancer epigenetics: above and beyond.

Authors:  Mariana Brait; David Sidransky
Journal:  Toxicol Mech Methods       Date:  2011-05       Impact factor: 2.987

Review 2.  The prognostic and functional role of microRNAs in acute myeloid leukemia.

Authors:  Guido Marcucci; Krzysztof Mrózek; Michael D Radmacher; Ramiro Garzon; Clara D Bloomfield
Journal:  Blood       Date:  2010-11-02       Impact factor: 22.113

3.  SIRT6: a master epigenetic gatekeeper of glucose metabolism.

Authors:  Lei Zhong; Raul Mostoslavsky
Journal:  Transcription       Date:  2010 Jul-Aug

4.  Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth.

Authors:  Changliang Shan; Shannon Elf; Quanjiang Ji; Hee-Bum Kang; Lu Zhou; Taro Hitosugi; Lingtao Jin; Ruiting Lin; Liang Zhang; Jae Ho Seo; Jianxin Xie; Meghan Tucker; Ting-Lei Gu; Jessica Sudderth; Lei Jiang; Ralph J DeBerardinis; Shaoxiong Wu; Yuancheng Li; Hui Mao; Peng R Chen; Dongsheng Wang; Georgia Zhuo Chen; Sagar Lonial; Martha L Arellano; Hanna J Khoury; Fadlo R Khuri; Benjamin H Lee; Daniel J Brat; Keqiang Ye; Titus J Boggon; Chuan He; Sumin Kang; Jun Fan; Jing Chen
Journal:  Mol Cell       Date:  2014-07-17       Impact factor: 17.970

5.  Regulation of cellular metabolism by protein lysine acetylation.

Authors:  Shimin Zhao; Wei Xu; Wenqing Jiang; Wei Yu; Yan Lin; Tengfei Zhang; Jun Yao; Li Zhou; Yaxue Zeng; Hong Li; Yixue Li; Jiong Shi; Wenlin An; Susan M Hancock; Fuchu He; Lunxiu Qin; Jason Chin; Pengyuan Yang; Xian Chen; Qunying Lei; Yue Xiong; Kun-Liang Guan
Journal:  Science       Date:  2010-02-19       Impact factor: 47.728

6.  Acute myeloid leukemia in patients older than 75: prognostic impact of FLT3-ITD and NPM1 mutations.

Authors:  Pierre Hirsch; Ghazi Qassa; Christophe Marzac; Ruoping Tang; Jean-Yves Perrot; Françoise Isnard; Mohamad Mohty; Jean Pierre Marie; Ollivier Legrand
Journal:  Leuk Lymphoma       Date:  2014-06-16

7.  Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia.

Authors:  Xabier Agirre; Amaia Vilas-Zornoza; Antonio Jiménez-Velasco; José Ignacio Martin-Subero; Lucia Cordeu; Leire Gárate; Edurne San José-Eneriz; Gloria Abizanda; Paula Rodríguez-Otero; Puri Fortes; José Rifón; Eva Bandrés; María José Calasanz; Vanesa Martín; Anabel Heiniger; Antonio Torres; Reiner Siebert; José Román-Gomez; Felipe Prósper
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

Review 8.  Role of microRNAs in the Warburg effect and mitochondrial metabolism in cancer.

Authors:  Li-Hui Jin; Chen Wei
Journal:  Asian Pac J Cancer Prev       Date:  2014

9.  MicroRNA-26a regulates glucose metabolism by direct targeting PDHX in colorectal cancer cells.

Authors:  Bing Chen; Yuling Liu; Xuewen Jin; Weiliang Lu; Jingjing Liu; Zijing Xia; Qiong Yuan; Xia Zhao; Ningzhi Xu; Shufang Liang
Journal:  BMC Cancer       Date:  2014-06-16       Impact factor: 4.430

10.  MicroRNA-26a-5p and microRNA-23b-3p up-regulate peroxiredoxin III in acute myeloid leukemia.

Authors:  Wenjie Jiang; Jie Min; Xiaohui Sui; Yanyan Qian; Ying Liu; Zhaojian Liu; Haibin Zhou; Xi Li; Yaoqin Gong
Journal:  Leuk Lymphoma       Date:  2014-06-25
View more
  2 in total

Review 1.  Emerging roles of SIRT6 in human diseases and its modulators.

Authors:  Gang Liu; Haiying Chen; Hua Liu; Wenbo Zhang; Jia Zhou
Journal:  Med Res Rev       Date:  2020-12-16       Impact factor: 12.944

2.  Knockdown of IARS2 Inhibited Proliferation of Acute Myeloid Leukemia Cells by Regulating p53/p21/PCNA/eIF4E Pathway.

Authors:  Hong Li; Yaning Tian; Xiang Li; Bin Wang; Dongzhi Zhai; Yingying Bai; Changhu Dong; Xu Chao
Journal:  Oncol Res       Date:  2019-03-04       Impact factor: 5.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.